

13th ADVANCED COURSE OF VACCINOLOGY- 2012

MONDAY 14 MAY 2012		Theme Coordinator : Adam Finn (Bristol, UK)	
09 :00	Opening	Benoit Miribel , General Director, Fondation Mérieux	
09 :15	Definition of the course objectives	Paul-Henri Lambert , Director of the ADVAC Course	
SESSION 1.- THE MULTIFACETED NATURE OF VACCINOLOGY		Chairpersons: Marie-Paule Kiény (WHO) and Claire-Anne Siegrist	
09:40-10:20	Opening Lecture: The history of vaccinology and the present vaccine pipe line	Stanley Plotkin , University of Pennsylvania	OK
10:20-10:40	Discussion		
10:40-11:10	Break		
11:10-11:55	Impact of vaccination on disease epidemiology	Roy Anderson , Imperial College, London, UK	
11:55-12:20	Discussion		
12:30-14:00	<u>Lunch</u>		
14:00-14:30	Success and challenges with Rotavirus vaccines:	Umesh Parashar CDC	
14:30-14:50	Discussion		
14:50-15:20	Public and media perception of vaccination	David Salisbury , Department of Health, UK	
15:20-15:40	discussion		
15:40-16:00	Break		
16:00-16:40	Keynote lecture: Access to cost-effective vaccination at global level	Seth Berkley , GAVI Alliance	
16:40-17:00	discussion		
17:00-19:30	Self-presentation of individual participants (background, interests in life...) & Welcome reception		

TUESDAY 15 MAY 2012

SESSION 2 - HOW VACCINES WORK		Chairpersons: Adam Finn and Daniel Pinschewer (UNIGE)
09:00-09:30	How are vaccine responses elicited? What a vaccinologist should know about the basic aspects of immunological responses a- B-cell responses	Claire-Anne Siegrist , University of Geneva
09:30-10:00	Discussion	
10:00-10:30	<u>Break</u>	
10:30-11:00	What a vaccinologist should know about the basic aspects of immunological responses b- T-cell responses	Claire-Anne Siegrist , University of Geneva
11:00-11:30	Discussion	
11:30-12:20	Use and limitations of correlates of immunity in vaccinology:	Stanley Plotkin and Andrew Pollard , University of Oxford
12:20-12:50	Common discussion	
	<u>Lunch</u>	
14:15-14:45	Immunological basis for responses to mucosal vaccines	Adam Finn , University of Bristol
14:45-15:05	Discussion	
15:05-16:00	Vaccines and Immunological memory Quiz and general discussion	Claire-Anne Siegrist , University of Geneva
16:30-17:10	Special lecture: Vaccine-induced Immunological memory	Rafi Ahmed , Emory University
17:10-17:30	Discussion	
17:45	Debate with drinks on a hot topic : narcolepsy?	Chair Adam Finn with Hanna Nohynek

WEDNESDAY 16 MAY 2012		Theme Coordinator : Hanna Nohynek (THL, Helsinki)
	SESSION 3 – DECISION-MAKING IN VACCINE RESEARCH AND PRECLINICAL DEVELOPMENT	Chairpersons: Luc Hessel & Georges Thiry
09:00-09:30	How do vaccines cause adverse events ?	Neal Halsey , Johns Hopkins B. School of Public Health, Baltimore
09:30-09:50	discussion	
09:50-10:20	Vaccine adjuvants	Martin Friede , WHO, Geneva
10:20-10:40	Discussion	
10:40-11:00	Break	
11:00-11:30	From pre-clinical research to vaccine development: Examples of go-no-go decisions	Georges Thiry , PATH
11:30-11:50	Discussion	
11:50-12:20	Advances in vaccine and immunization technologies	Carole Heilman , NIAID
12:20-12:40	Discussion	
	Lunch	
14:00-14:30	Special lectures: New vaccines in development (1) HIV vaccines	Brigitte Autran , INSERM, France
14:30-14:50	Discussion	
15:00-17:00	Regulatory considerations e.g. re:new adjuvants Round table debate	Norman Baylor (BCG), Pieter Neels (Federal Agency for Medicinal and Health Products Brussels & CHMP-EMA) – XXXXXXX , GSKBio and Michael Decker (Sanofi Aventis.)
17:00-17:30	Lessons from pitfalls experienced in clinical trials and in the registration process	Luc Hessel , Sanofi Pasteur MSD, Lyon,
17:30-17:50	discussion	

		Theme Coordinator : Hanna Nohynek (THL, Helsinki)
THURSDAY 17 MAY 2012		
SESSION 4 - ASSESSING VACCINES IN CLINICAL TRIALS (I)		Chairpersons:
09:00-09:40	Clinical trials: an overview of issues to be considered	Myron Levine , University of Maryland, Baltimore, USA
09:40-10:00	Discussion	
10:00-10:30	Introduction to statistical aspects of clinical trials 1- Defining sample size: practical approaches and examples	Peter Smith , LSTMH, UK
10:30-10:50	Discussion	
10:50-11:00	<u>Break</u>	
11:00-13:45	How to design, recruit volunteers for, and analyze the results of selected phase II trials Small group exercise: How to design a phase II trial - Group 1: Group 2: - Group 3: Group 4: Group 5: Statistical approaches-exercise- Group 6: -	
12:40-13:10	<i>lunch buffet</i>	
13:50- 14:20	Essential practical aspects in conducting phase III trials	Hanna Nohynek , THL, Helsinki
14:20-14:40	Discussion	
14:40-15:15	Special lectures: New vaccines in development (2) The challenge of developing new tuberculosis vaccines	
15:15-15:35	Discussion	David Lewis , Uni Surrey UK
15:35-15:55	<u>Break</u>	
15:55-16:25	Clinical trials: role of a DSMB- (with several examples of intervention)	Penny Heaton , Novartis Vaccines & Diagnosis
16:25-16:40	Discussion	
16:40-17:10	Assessing herd protection	John Clemens , London
17:10-17:30	Discussion	

FRIDAY 18 MAY 2012		Theme Coordinator : Neal Halsey (Baltimore)
SESSION 5– VACCINE SAFETY - ASSESSMENT OF ADVERSE EFFECTS		Chairpersons: Kari Johanssen and Neal Halsey
08:45-09:15	Lessons from previous adverse effects of vaccination and Assessment of causal relationships	Neal Halsey , Johns Hopkins B. School of Public Health, Baltimore
09:15-09:35	Discussion	
09:35-10:05	Immunological safety of vaccination (Autoimmune and allergic diseases)	Paul-Henri Lambert , Dir ADVAC
10:05-10:25	Discussion	
10:25-10:40	Break	
10:40-11:10	Population-based post-licensure surveillance	Steve Black , Cincinnati Children's Hospital Medical Center
11:10-11:40	Immunization safety in developing country vaccination programs	Philippe Duclos , WHO
11:40-12:20	Common Discussion	
	<u>Lunch</u>	
13:30-14:00	Risk communication: An overview	Noni McDonald , Dalhousie Univ, Halifax Canada
14:00-14:20	Discussion	
SESSION 6– ASSESSING VACCINES IN CLINICAL TRIALS (II)		Chairperson: Hanna Nohynek
14:20-14:50	Introduction to statistical aspects of clinical trials- 2- Statistical assessment of phase 3 trials- 30 min	Peter Smith , LSTMH, UK
14:50-15:10	Discussion	
15:15-18:00	Small group exercise 2: Designing and analysing the results of 3 selected phase III trial (pneumococcal conjugate vaccine in The Gambia, among Navajo Indians in the U.S. and in South Africa)	Objective: To understand how to critically appraise and compare phase III trial results
	Introduction to the group work Exercise:	Hanna Nohynek
	Group 1:- Facilitator: Edwin Asturias Group 2: - Facilitator: Hanna Nohynek Group 3: - Facilitator: Steve Black Group 4: - Facilitator: TBD Group 5: - Facilitator: Peter Smith	

		Theme Coordinator : Edwin Asturias (Guatemala City)
	SATURDAY 19 MAY 2012	
	SESSION 7- ETHICAL ISSUES Ethical issues related to clinical trials – Revisiting the Helsinki Declaration	Chairpersons: Betty Dodet and Kari Johanssen
08:45-09:45	Clinical trials: Ethical issues basic principles & practical approaches Specific issues in developing countries	Catherine Slack (University of KwaZulu-Natal, South Africa) Peter Ndumbe (Cameroon)
09:45-10:15	Common discussion	
10:15-12:45	Small group exercise 3: Ethical issues –topics to be selected with facilitators	Coordinated by Kari Johanssen & Betty Dodet (Lyon)
	Group 1:- Facilitator: Hanna Nohynek Group 2: - Facilitator: Catherine Slack Group 3: - Facilitator: Noni McDonald Group 4: - Facilitator: Betty Dodet Group 5: - Facilitator: Kari Johanssen Group 6: - Facilitator: TBD	

		Theme Coordinator : Mark Miller (Bethesda)
	MONDAY 21 MAY 2012	
08:40-09:00	Review and conclusions of the 23 May Ethics session	Cathy Slack
	SESSION 8.1- INTRODUCING NEW VACCINES INTO VACCINATION PROGRAMMES Approaches to help the decision-making process Case Case # 1 - Pneumococcal and Influenza vaccines in infants and adults	Chairperson: Marie-Paule Kieny , WHO and Bernard Fritzell , Lyon
09:00-09:30	Understanding responses to polysaccharide and conjugate vaccines in infants and adults	David Goldblatt , Institute of Child Health, London
09:30-09:50	Discussion	
09:50-10:20	Understanding vaccine responses in the elderly	Richard Aspinall , Cranfield University, UK
10:20-10:40	Discussion	
10:40-11:00	break	
11:00-11:35	Pneumococcal conjugate vaccines: overview-	Ron Dagan , Soroka Medical Center, Beer Sheva
11:35-12:10	Pneumococcal vaccines: role of viral infections, ecological aspects, and issues related to adult vaccination	Keith Klugman Emory Univ
12:10-12:40	Discussion	
12:30-14:00	Lunch	
14:00-14:40	Influenza biology , new vaccines and vaccination strategies for different age groups	Kathy Neuzil , PATH, Seattle
14:40-15:00	Discussion	
15:00-15:30	Modeling the impact of adult/elderly vaccination (influenza, pneumo, zoster)	John W Edmunds , London School of Hygiene and Tropical Medicine
15:30-15:50	Discussion and debate	
15:50-16:10	Break	
16:10-16:50	Special lecture: The population biology of bacterial pathogens and its importance for vaccination strategies	Richard Moxon , Oxford University
16:50-17:10	Discussion -	
17:10-17:40	Special lecture: vaccines in development The challenge of malaria vaccines-	Vasee Moorthy , WHO
17:40-18:00	Discussion	
18:00	Debate with drinks on hot topic e.g. adult vaccination	

TUESDAY 22 MAY 2012		Theme Coordinator : Mark Miller (Bethesda)
	SESSION 8.2 - INTRODUCING NEW VACCINES INTO VACCINATION PROGRAMMES (2)	Chairperson: Juhani Eskola , THL, Finland and Alan Shaw, Vaxinnate
	Case-specific study #2: Meningococcal vaccines	
09:00-09:30	Approaches towards new Meningococcal vaccines	Giuseppe Del Giudice, Novartis Vaccines
09:30-09:50	Discussion	
09:50-10:20	The MenA-conjugate experience	Brian Greenwood, UK
10:20-10:40	Discussion	
10:40-11:00	<u>Break</u>	
	Decision-making process for the use of new vaccines at national or regional level	
11:00-11:30	Role of disease burden assessment in the decision-making process	Brad Gessner, Association pour la Médecine Préventive, AMP
11:30-11:50	Discussion	
11:50-12:20	Health economics as a tool in analyzing Vaccine Policy Options	Mark Miller, Fogarty International Center
12:20-12:40	Discussion	
12:40-13:40	Lunch buffet	
13:40-14:10	Challenges and solutions in making evidence-based national vaccination policies and recommendations	Kamel Senouci, SIVAC
14:10-14:30	Discussion	
14:30-17:30	Small group exercise 4: Decision-making for the evaluation and impact of new vaccines introduced in selected countries: safety and effectiveness	organized by Kari Johanssen, ECDC and Hanna Nohynek
	Objective: To learn what facts are needed in a decision-making process and how other factors influence the outcome Group 1 Rota Group 2 Rota Rana Hajeh Group 3 HPV Alan Shawn Group 4 HPV Edwin Asturias Group 5 PCV Juhani Eskola Group 6 PCV Bernard Fritzell	
17:40	Soccer game North vs South of the World	

		Theme Coordinator : Neal Halsey (Baltimore)
	WEDNESDAY 23 MAY 2012	
	SESSION 9 - SELECTING APPROPRIATE VACCINATION STRATEGIES	Chairpersons: Janet Englund
	1. Vaccination and pregnancy	
09:00-09:30	Main issues and applications in developed and developing countries	Janet Englund , Children's Hospital and Regional Medical Center, Seattle
09:30-09:50	Discussion	
	2. Vaccination in early life	
09:50-10:20	Advantages and limitations	Claire-Anne Siegrist , University of Geneva
10:20-10:40	Discussion	
10:40-11:00	Break	
	3. Vaccination schedules	
11:00-11:30	Past, present and future – Is there some rationale?	Edwin Asturias
11:30-11:50	Discussion	
11:50-14:30	Parallel working group sessions (with sandwich lunch)	
	1. Capacity Building in Developing Countries -	Charles Mgone (Executive Director EDCTP) Arnd Hoeveler , EC, Brussels, and Alan Shaw , Vaxinnate
	2. National decision making for immunization programmes	Melinda Wharton , CDC, and Philippe Duclos ,WHO
	3. Clinical vaccinology : patients' problem solving	CA Siegrist and Alessandro Diana
	4. new approaches towards vaccination e-registries	Kari Johanssen (ECDC) and
14:30-15:00	Info on main ADVAC sponsors activities- Grant opportunities in vaccinology: The EC programmes	Arnd Hoeveler , Head, Health and Biotechnology, EC, Brussels and Charles Mgone , Executive Director EDCTP
15:00-15:20	Discussion	
15:20-15:40	Break	
	Special lectures: New vaccines	
15:40-16:10	Prospects for dengue and JE vaccines	Hal Margolis , CDC
16:10-16:30	Discussion	
16:30-17:10	PLOTKIN LECTURE	Trevor Mundel , BMFG or Stanley Plotkin
17:10-17:40	discussion	
18:00	Departure to Château de Menthon visit and special reception -	

		Theme Coordinator : Edwin Asturias (Guatemala City)
	THURSDAY 24 MAY 2012	
		Chairperson: Edwin Asturias
09:00-09:40	Vaccination in immune-compromised individuals, including HIV positive patients	Claire-Anne Siegrist , University of Geneva
09:40-10:00	discussion	
	<u>Special lectures: New vaccines</u>	
10:00-10:30	CMV vaccines in development	Stanley Plotkin
10:30-10:50	Discussion	
	Break	
11:10-11:40	HPV vaccines	xxx
11:40-12:00	Discussion	
12:00-12:30	Challenges for making vaccines : essential steps	Phil Gomez
12:30-12:50	Discussion	
12:50-13:45	<u>Buffet Lunch</u>	
13:45-14:15	Role of DC vaccine Industry for meeting the Global needs	Suresh Jadhav , Serum Institute of India, Chair DCVMN (30 min)
14:15-14:35	Discussion	
	Elimination or Eradication strategies?	
14:35-15:35	Polio, Measles and rubella	Roland Sutter WHO – 30 min Peter Streble, WHO- 30 min
15:35-16:15	General discussion coordinated by	Stanley Plotkin-
16:15	<u>Presentations by participants and poster discussion</u> Brief presentations by participants and poster discussio	

		Thematic supervisor : Edwin Asturias (Guatemala City)
	FRIDAY 25 MAY 2012	
	SESSION 10: FACING THE MEDIA	Chairperson: Edwin Asturias
09:00-12:30	Interactive session	Deborah Hall , Broadcaster and media affairs consultant, London,
	Introduction to media dynamics: How to best deliver vaccinology r elated messages to different interest groups Lunch	(organized by Edwin Asturias)
14:00-15:00	CME credits Diploma ceremony – Distribution of CD Roms with course slides	Stanley Plotkin and Paul Henri Lambert
15:00	Closure of the Course The educational quality of the course will be certified by Prof. Claire-Anne Siegrist and Dr Hanna Nohynek (CME related issues)	